Mayorga A J, Dalvi A, Page M E, Zimov-Levinson S, Hen R, Lucki I
Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6140, USA.
J Pharmacol Exp Ther. 2001 Sep;298(3):1101-7.
The development of serotonin receptor knockout mice has provided an opportunity to study antidepressant drug effects in animals with targeted genetic deletion of receptors involved in antidepressant responses. In the current study, the effects of two types of antidepressant drugs, the selective serotonin reuptake inhibitors fluoxetine and paroxetine and the selective norepinephrine reuptake inhibitor desipramine, were examined in 5-hydroxytryptamine (5-HT)(1A) and 5-HT(1B) receptor mutant mice using the tail suspension test (TST). Under baseline conditions, the immobility of 5-HT(1A) receptor mutant mice, but not 5-HT(1B) receptor mutant mice, was significantly lower than that of wild-type mice. The decreased baseline immobility in 5-HT(1A) receptor mutant mice was reversed by pretreatment with alpha-methyl-para-tyrosine, but not by para-chlorophenylalanine, suggesting mediation by enhanced catecholamine function. In wild-type mice, fluoxetine (10.0--20.0 mg/kg i.p.) and desipramine (5.0--20.0 mg/kg i.p.) both significantly decreased immobility in the TST. In 5-HT(1A) receptor mutant mice, desipramine (20.0 mg/kg i.p.) significantly decreased immobility, whereas fluoxetine (20.0 mg/kg i.p.) and paroxetine (20.0 mg/kg i.p.) had no effect. The immobility of 5-HT(1B) receptor mutant mice was decreased similarly by desipramine (5.0--20.0 mg/kg i.p.). However, the effect of low doses of fluoxetine were significantly augmented in the 5-HT(1B) receptor mutant mice (2.5--20.0 mg/kg i.p.) compared with wild-type mice. Administration of selective 5-HT receptor antagonists in wild-type mice partially reproduced the phenotypes of the mutant mice. These results suggest that 5-HT(1A) and 5-HT(1B) receptors have different roles in the modulation of the response to antidepressant drugs in the TST.
5-羟色胺受体基因敲除小鼠的培育为研究抗抑郁药物在涉及抗抑郁反应的受体发生靶向基因缺失的动物体内的作用提供了契机。在本研究中,使用悬尾试验(TST)检测了两种抗抑郁药物——选择性5-羟色胺再摄取抑制剂氟西汀和帕罗西汀以及选择性去甲肾上腺素再摄取抑制剂地昔帕明——对5-羟色胺(5-HT)(1A)和5-HT(1B)受体突变小鼠的影响。在基线条件下,5-HT(1A)受体突变小鼠的不动时间显著低于野生型小鼠,但5-HT(1B)受体突变小鼠并非如此。5-HT(1A)受体突变小鼠基线不动时间的降低可被α-甲基-对-酪氨酸预处理逆转,但不能被对氯苯丙氨酸逆转,提示其通过增强儿茶酚胺功能介导。在野生型小鼠中,氟西汀(10.0 - 20.0mg/kg腹腔注射)和地昔帕明(5.0 - 20.0mg/kg腹腔注射)均显著降低了TST中的不动时间。在5-HT(1A)受体突变小鼠中,地昔帕明(20.0mg/kg腹腔注射)显著降低了不动时间,而氟西汀(20.0mg/kg腹腔注射)和帕罗西汀(20.0mg/kg腹腔注射)则无作用。地昔帕明(5.0 - 20.0mg/kg腹腔注射)同样降低了5-HT(1B)受体突变小鼠的不动时间。然而,与野生型小鼠相比,低剂量氟西汀(2.5 - 20.0mg/kg腹腔注射)对5-HT(1B)受体突变小鼠的作用显著增强。在野生型小鼠中给予选择性5-HT受体拮抗剂部分重现了突变小鼠的表型。这些结果表明,5-HT(1A)和5-HT(1B)受体在TST中对抗抑郁药物反应的调节中具有不同作用。